NS-580 Phase 1 trial as a treatment for endometriosis
First written in FY2017-Q1. 22 of 27 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「The Phase 2b trial targeting endometriosis, which had been underway since June 2022, and the Phase 2 trial targeting chronic prostatitis/chronic pelvic pain syndrome, which had been underway since June 2023, are each currently temporarily suspended.」
The status of the two NS-580 trials as temporarily suspended is being reiterated. - FY2024SoftenedAnnual report
「The Phase 2b trial targeting endometriosis, which had been underway since June 2022, and the Phase 2 trial targeting chronic prostatitis/chronic pelvic pain syndrome, which had been underway since June 2023, were each temporarily suspended.」
The status of NS-580's Phase 2b trial for endometriosis and Phase 2 trial for chronic prostatitis/chronic pelvic pain syndrome changed from ongoing to temporarily suspended. - FY2024-Q3RestatedAnnual report
「For NS-580, a Phase 2b trial targeting endometriosis has been underway since June 2022. A Phase 2 trial targeting chronic prostatitis/chronic pelvic pain syndrome has also been underway since June 2023.」
The Phase 2b trial of NS-580 for endometriosis and the Phase 2 trial for chronic prostatitis/chronic pelvic pain syndrome remain ongoing. - FY2024-Q2RestatedAnnual report
「For NS-580, a Phase 2b trial targeting endometriosis has been underway since June 2022. A Phase 2 trial targeting chronic prostatitis/chronic pelvic pain syndrome has also been underway since June 2023.」
The Phase 2b trial of NS-580 for endometriosis and the Phase 2 trial for chronic prostatitis/chronic pelvic pain syndrome remain ongoing. - FY2024-Q1AdvancedAnnual report
「For NS-580, a Phase 2b trial targeting endometriosis has been underway since June 2022. In addition, a Phase 2 trial targeting chronic prostatitis/chronic pelvic pain syndrome was initiated in June 2023.」
In addition to the Phase 2b trial for endometriosis, a Phase 2 trial for chronic prostatitis/chronic pelvic pain syndrome was initiated for NS-580 in June 2023. - FY2023RestatedAnnual report
「A Phase 2b trial of NS-580, a treatment for endometriosis, has been underway since June 2022.」
The Phase 2b trial of NS-580 initiated in June 2022 remains ongoing. - FY2023-Q2RestatedAnnual report
「A Phase 2b trial of NS-580, a treatment for endometriosis, has been underway since June 2022.」
The Phase 2b trial of NS-580 initiated in June 2022 remains ongoing. - FY2023-Q1AdvancedAnnual report
「The Phase 2a trial of NS-580, a treatment for endometriosis, was completed, and a Phase 2b trial was initiated in June 2022.」
The NS-580 Phase 2a trial was completed, and the program advanced to a Phase 2b trial in June 2022. - FY2022-Q3RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2022-Q2RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2022-Q1RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2021RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2021-Q3RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2021-Q2RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2021-Q1RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 2a trial remains ongoing. - FY2020-Q3RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, has been underway since July 2017.」
The Phase 2a trial of NS-580 initiated in July 2017 remains ongoing. - FY2020-Q2RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, has been underway since July 2017.」
The Phase 2a trial of NS-580 initiated in July 2017 remains ongoing. - FY2020-Q1RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, has been underway since July 2017.」
The Phase 2a trial of NS-580 initiated in July 2017 remains ongoing. - FY2019-Q3RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, has been underway since July 2017.」
The Phase 2a trial of NS-580 initiated in July 2017 remains ongoing. - FY2019-Q2RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, was initiated in July of the previous year.」
The status of the Phase 2a trial of NS-580 initiated in July of the previous year is being reiterated. - FY2019-Q1RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, was initiated in July of the previous year.」
The status of the Phase 2a trial of NS-580 initiated in July of the previous year is being reiterated. - FY2018-Q3RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, was initiated in July 2017.」
The status of the Phase 2a trial initiated in July 2017 for NS-580 is being reiterated. - FY2018-Q2RestatedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, was initiated in July 2017.」
The status of the Phase 2a trial initiated in July 2017 for NS-580 is being reiterated. - FY2018-Q1AdvancedAnnual report
「A Phase 2a trial of NS-580, a treatment for endometriosis, was initiated in July 2017.」
NS-580 advanced from the previous Phase 1 trial to the initiation stage of a Phase 2a trial. - FY2017-Q3RestatedAnnual report
「A Phase 1 trial of NS-580, a treatment for endometriosis, is currently underway.」
The NS-580 Phase 1 trial remains ongoing. - FY2017-Q2RestatedAnnual report
「A Phase 1 trial of NS-580, a treatment for endometriosis, was initiated in April 2015.」
The status of the initiation of the NS-580 Phase 1 trial is being reiterated. - FY2017-Q1First statedAnnual report
「A Phase 1 trial of NS-580, a treatment for endometriosis, was initiated in April 2015.」
It was stated that a Phase 1 trial of NS-580 targeting endometriosis was initiated in April 2015.